Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

    Virtual Booth

    Contact Supplier

    Coral

    Virtual Booth

    Contact Supplier

    ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

    Virtual Booth

    Contact Supplier

    Menu

    Taladegib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Endeavor Bio' Ph 2a Taladegib Results at ERS Congress 2025
    Endeavor Bio' Ph 2a Taladegib Results at ERS Congress 2025

    10 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-10/endeavor-biomedicines-to-present-results-from-phase-2a-trial-of-taladegib-env-101-in-an-alert-sess

    PHARMAWEB
    10 Sep 2025
    Share Share
    Endeavor BioMedicines Names ILD Expert Lisa Lancaster CMO
    Endeavor BioMedicines Names ILD Expert Lisa Lancaster CMO

    02 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250402562765/en/Endeavor-BioMedicines-Appoints-Internationally-Renowned-ILD-Expert-Lisa-Lancaster-M.D.-as-Chief-Medical-Officer

    BUSINESSWIRE
    02 Apr 2025
    Share Share
    Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101
    Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101

    06 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230906375636/en

    BUSINESSWIRE
    06 Sep 2023
    Share Share
    Endeavor Doses First Patient in Phase 2 Oncology Study of ENV-101 (Taladegib)
    Endeavor Doses First Patient in Phase 2 Oncology Study of ENV-101 (Taladegib)

    25 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220525005283/en

    BUSINESSWIRE
    25 May 2022
    Share Share
    Endeavor Bio Closes $101M Series B Financing for Precision Medicine Pipeline
    Endeavor Bio Closes $101M Series B Financing for Precision Medicine Pipeline

    07 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220207005151/en

    BUSINESSWIRE
    07 Feb 2022
    Share Share
    Endeavor BioMedicines Doses First Patient in Phase 2 of Taladegib for IPF
    Endeavor BioMedicines Doses First Patient in Phase 2 of Taladegib for IPF

    22 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210922005035/en

    BUSINESSWIRE
    22 Sep 2021
    Share Share